155,000 Shares in Delcath Systems, Inc. $DCTH Bought by Royce & Associates LP

Royce & Associates LP purchased a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 155,000 shares of the company’s stock, valued at approximately $1,566,000. Royce & Associates LP owned 0.44% of Delcath Systems at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of DCTH. Millennium Management LLC lifted its holdings in Delcath Systems by 34.1% during the first quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock worth $5,373,000 after acquiring an additional 107,391 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Delcath Systems by 58.7% in the first quarter. Goldman Sachs Group Inc. now owns 123,487 shares of the company’s stock valued at $1,572,000 after buying an additional 45,695 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Delcath Systems by 229.1% in the second quarter. JPMorgan Chase & Co. now owns 168,245 shares of the company’s stock valued at $2,288,000 after buying an additional 117,118 shares during the period. Legal & General Group Plc bought a new stake in shares of Delcath Systems in the second quarter valued at $46,000. Finally, Rhumbline Advisers bought a new stake in shares of Delcath Systems in the second quarter valued at $586,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Stock Performance

NASDAQ:DCTH opened at $10.78 on Friday. Delcath Systems, Inc. has a 52-week low of $8.12 and a 52-week high of $17.35. The firm has a market cap of $372.13 million, a price-to-earnings ratio of 1,078.00 and a beta of 0.54. The business’s fifty day moving average is $10.45 and its 200 day moving average is $9.96.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.07. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%.The company had revenue of $24.99 million for the quarter, compared to analyst estimates of $23.51 million. Equities analysts predict that Delcath Systems, Inc. will post -0.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DCTH shares. Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. BTIG Research lowered their target price on Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Evercore set a $27.00 target price on Delcath Systems in a research note on Thursday, February 26th. Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Zacks Research lowered Delcath Systems from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $22.50.

Delcath Systems Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.